Altered activity of a protein called PUM1 plays a key role in the development of pulmonary hypertension (PH), according to a new study done in animal and cell models. “Our study establishes PUM1 as a critical driver of PH pathogenesis [disease development],” the scientists wrote, adding that “this discovery…
News
Tiakis Biotech is set to advance its experimental therapy tiprelestat into a Phase 2 clinical trial for pulmonary arterial hypertension (PAH), after successfully finalizing the data package required for regulatory review. The planned study, dubbed ATHENA, will be led by Stanford University and will enroll about 90 patients…
Overproduction of the naturally occurring hormone adrenomedullin, or ADM, helped protect neonatal mice from experimental bronchopulmonary dysplasia (BPD) and related pulmonary hypertension (PH), a study reports. “These findings strongly support the potential of ADM therapy for infants with BPD-PH,” the researchers wrote in the study, “Adrenomedullin…
Two proteins associated with the aggregation and activation of platelets may serve as biomarkers of chronic thromboembolic pulmonary hypertension (CTEPH) severity and progression, according to a study conducted in China. The proteins, PAD4 and NOX2, were elevated in platelets of people with CTEPH compared with healthy individuals, suggesting they may…
Merck Canada has taken what it called a “critical step” toward making its approved therapy Winrevair (sotatercept-csrk) — which works to improve exercise capacity and reduce the risk of clinical worsening events in people with pulmonary arterial hypertension (PAH) — accessible to eligible patients in the country. The…
Merck is planning a Phase 3 trial testing Winrevair (sotatercept-csrk) in people with combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF). CpcPH is a form of pulmonary hypertension due to left heart disease, marked by elevated blood pressure in the vessels…
Researchers in the U.S. have found that exposure to low oxygen levels — known as hypoxia — early in life can cause pulmonary hypertension (PH) by permanently altering lung blood vessel development. The team used a new mouse model they designed to better reflect a severe form of PH…
CM5480, an experimental therapy being developed by Calcimedica, improved blood flow and heart-function measures in a rat model of pulmonary arterial hypertension (PAH), a new study reports. The therapy was helpful when used on its own and provided additional benefits when combined with two currently available…
Cereno Scientific is seeking a green light from the U.S. Food and Drug Administration (FDA) to launch a global clinical trial testing its oral therapy CS1 — a repurposed drug now used for treating seizures — in people with pulmonary arterial hypertension (PAH). In PAH, the company hopes the…
This article is provided by our partner, the American Lung Association. It has been reviewed by Bionews for accuracy and relevance. The views and opinions expressed are those of the author and do not necessarily reflect the views of Bionews or Pulmonary Hypertension News. How often do you think…
Researchers have identified distinct genetic changes tied to the severity of idiopathic pulmonary arterial hypertension (IPAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Data showed that the expression (activity) of the ABCA3 gene was lower in IPAH patients, while that of the SMAD9 gene was increased in CTEPH, particularly…
The first clinical site is now active for a global Phase 3 study that will evaluate Gossamer Bio’s therapy candidate seralutinib in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Dubbed SERANATA, the study aims to enroll about 480 people with PH-ILD, ages 18 to 80. No…
